

1646
PATENT
Attorney Docket No.: A-68064-1/RFT/RMS/RMK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DAHIYAT et al.

Serial No. 09/574,443

Filed: May 19, 2000

For: NOVEL PROTEINS WITH
INSULIN-LIKE ACTIVITY
USEFUL IN THE TREATMENT OF
DIABETES

Examiner: SAOUD, C.

Group Art Unit: 1646

RECEIVED

OCT 12 2001

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, DC 20231 on Sept. 27, 2001.

Signed:

Marjorie Jost
Marjorie Jost

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
AND STATEMENT OF RELATEDNESS

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO-1449. Copies of the references are enclosed.

None of the foregoing references are believed to disclose the invention as claimed. Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application.

Serial No.: 09/574,443

Filed: May 19, 2000

Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

Further, in accordance with the provisions of 37 C.F.R. §§ 1.97(c) and 1.97(e)(1), the undersigned certifies that references 48-53 listed on the enclosed form PTO-1449 were first cited in a Communication Relating to the Results of the Partial International Search dated June 1, 2001, for a counterpart PCT application. A copy of the Communication for the counterpart PCT application is enclosed herewith.

As required by M.P.E.P. §2001.06(b) Applicant notes that the present application is related to the following patent applications: (1) U.S.S.N. 09/812,034, filed March 19, 2001; (2) U.S.S.N. 09/827,960, filed April 4, 2001; (3) U.S.S.N. 09/837,886, filed April 18, 2001; (4) U.S.S.N. 09/782,004, filed February 12, 2001; and (5) U.S.S.N. 09/927,790, filed Aug 10, 2001.


As far as is known to the undersigned, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required. While no fee is currently believed to be due, the Commissioner is authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 06-1300 (Our Order No. A-68064-1/RFT/RMS/RMK).

Respectfully submitted,

FLEHR, HOHBACH, TEST,
ALBRITTON & HERBERT

Dated: 9/26/01

Four Embarcadero Center
Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989


Renee M. Kosslak, Reg. No. 47,717 for
Robin M. Silva, Reg. No. 38,304